Record Product Revenue
Product revenue for Q3 2025 reached $52.7 million, a 15% year-over-year increase. The revenue increase was driven by strong platelet demand and growing IFC adoption.
Increased Revenue Guidance
Cerus raised its full-year 2025 product revenue guidance to $202 million to $204 million, reflecting confidence in continued momentum across their franchises.
Strong IFC Growth
IFC product revenue for Q3 was $3.9 million, a 70% increase from the previous year, with demand more than doubling as hospitals recognize its clinical and operational benefits.
Positive Non-GAAP Adjusted EBITDA
Cerus reported its sixth consecutive quarter of positive non-GAAP adjusted EBITDA, totaling $5 million for Q3 2025.
Expansion in Germany
Cerus was selected by the German Red Cross Blood Service to support the INITIATE study, marking an important step for potential growth in Germany.